Li Dan, Liu Xin, Liu Yang, Zhu Yue, Yang Dafu, Song Jincheng, Dai Zhaoxia
Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Onco Targets Ther. 2025 Apr 5;18:503-507. doi: 10.2147/OTT.S502112. eCollection 2025.
The effectiveness of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) has been established, leading the NCCN Guidelines to recommend it as a first-line treatment for patients with advanced mutation-positive non-small cell lung cancer (NSCLC). However, there is still controversy about the use of neoadjuvant TKI treatment for patients with stage III EGFR mutation-positive NSCLC. Here, we firstly report that a stage IIIA lung adenocarcinoma patient benefited from chemotherapy and dacomitinib as neoadjuvant targeted therapy based on G719X mutation, achieving a pathological downstaging and the chance of radical surgical resection. Our case describes dacomitinib use as neoadjuvant targeted therapy for EGFR positive advanced NSCLC and highlights the application of molecular testing for the better treatment decision making.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKIs）的有效性已得到确立，这使得美国国立综合癌症网络（NCCN）指南推荐将其作为晚期EGFR突变阳性非小细胞肺癌（NSCLC）患者的一线治疗方案。然而，对于Ⅲ期EGFR突变阳性NSCLC患者使用新辅助TKI治疗仍存在争议。在此，我们首次报告了一名ⅢA期肺腺癌患者，基于G719X突变，从化疗和达可替尼作为新辅助靶向治疗中获益，实现了病理降期并获得了根治性手术切除的机会。我们的病例描述了达可替尼作为EGFR阳性晚期NSCLC的新辅助靶向治疗的应用，并强调了分子检测在更好地做出治疗决策中的应用。
